Business Context and Reporting Period
This Form 8-K, filed on February 11, 2025, reports on Nukkleus Inc. (NUKK), a Delaware corporation. The filing details an amendment to a material definitive agreement entered into on December 15, 2024, regarding the acquisition of a controlling interest in Star 26 Capital Inc. ("Star"), a defense acquisition company. The reporting period focuses on the transaction amendments executed on February 11, 2025.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or margins for Nukkleus Inc. or Star. Instead, it outlines the financial structure of the acquisition and amendment:
- Acquisition Target: 51% controlling interest in Star 26 Capital Inc.
- Revised Total Consideration: Increased to $21,000,000 (up from $15,000,000).
- Cash Component: $5,000,000 (minimum).
- Debt Component (Investment Note): Increased to $16,000,000, maturing 12 months post-closing.
- Equity Component: Issuance of 2,385,170 shares of Nukkleus common stock to the seller.
- Warrant Component: Issuance of a five-year warrant to Star to purchase 6,907,859 shares at $1.50 per share.
- Pre-Closing Loan: Increased from $1,000,000 to $1,800,000.
Material Changes Versus Prior Period
The primary material change is the execution of Amendment No. 1 to the original Securities Purchase Agreement. Key changes include:
- Investment Increase: The total consideration for the 51% stake was raised by $6,000,000, driven entirely by an increase in the promissory note balance.
- Loan Increase: The amount Nukkleus will lend to Star prior to closing was increased by $800,000.
- Option Expiration Condition: A new provision states that the option to purchase the remaining 49% of Star will automatically expire if Star consummates an initial public offering (IPO) or direct listing on Nasdaq or NYSE.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Related Parties: Menachem Shalom, the CEO and a director of Nukkleus, is also a controlling shareholder, CEO, and director of Star. This constitutes a related-party transaction.
Risks and Contingencies:
- Debt Obligation: The transaction significantly increases Nukkleus's debt exposure via the $16,000,000 Investment Note.
- Dilution: The issuance of approximately 2.4 million shares and warrants for nearly 7 million shares may dilute existing shareholders.
- Option Expiry: The automatic expiration of the call option upon Star's IPO limits Nukkleus's ability to acquire full control if Star goes public independently.
Unusual Items: The filing notes that the summary provided is not complete and is qualified by the full text of the agreements attached as exhibits.
Important Facts for Investor Verification
- Verify the exact terms of the $16,000,000 Investment Note, including interest rates and covenants, in Exhibit 10.2.
- Confirm the financial health and valuation of Star 26 Capital Inc. to assess the $21,000,000 investment value.
- Review the related-party transaction disclosures regarding Menachem Shalom's dual roles.
- Assess the impact of the new $1.8 million pre-closing loan on Nukkleus's immediate liquidity.
- Understand the conditions under which the option to acquire the remaining 49% of Star expires (specifically regarding an IPO or direct listing).